Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Publication Date: November 18, 2022
Last Updated: January 31, 2023

Chapter 1: Detection and evaluation of HCV in CKD

1.1: Screening patients with chronic kidney disease (CKD) for hepatitis C virus (HCV) infection

We recommend screening all patients for HCV infection at the time of initial evaluation of CKD. (1, C)
314262
We recommend using an immunoassay followed by nucleic acid testing (NAT) if immunoassay is positive. (1, A)
314262

Chapter 2: Treatment of HCV infection in patients with CKD

We recommend that all patients with CKD (G1-G5), on dialysis (G5D), and kidney transplant recipients (G1T-G5T) with HCV be evaluated for direct-acting antiviral (DAA)-based therapy as outlined in Figure 1. (1, A)
314262
We recommend that the choice of specific regimen be based on prior treatment history, drug–drug interactions, GFR, stage of hepatic fibrosis, kidney and liver transplant candidacy, and comorbidities. (1, A)
If pangenotypic regimens are not available, HCV genotype (and subtype) should guide the choice of treatment (Figure 1).
314262

Overview

Title

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Authoring Organization